S&P 5007,659▼ 1.09%Nasdaq26,140▼ 2.15%Dow Jones52,002▼ 0.34%Nasdaq 10029,188▼ 2.50%VIX19.99▲ 21.45%US Dollar101.84▼ 0.21%Gold (GLD)382.01▼ 0.18%Oil (USO)161.76▲ 2.83%
Home › ISRG › Research report
← ISRG page
XStocksXray
Research report · 16 October 2026

Intuitive Surgical Inc (ISRG)

Health Care · Health Care Equipment · US stock · price as of 16 Oct 2026

Key indicators

Price$426.70
52-week range$328.57 – $603.88
Market cap$152.5B
P/E (trailing)49.0×
EV / EBITDA42.7×
Free-cash-flow yield2.1%
Dividend yield–
Revenue (last 12 months)$11.0B
Revenue growth (3y a year)17.4%
Operating margin31.3%
Return on invested capital22.1%
Net debt / EBITDA–

Fair value

Blended fair value$287.30 range $257 – $317
Versus priceOvervalued−33% to fair value
Peer multiples$237.85
Fundamentals-adjusted multiple$237.54
10-year DCF (market-scaled)$386.49
Earnings power value (floor, not blended)$96.23
Model uncertaintyMedium

X-Ray Score

61/ 100 · High confidence · ahead of 72% of sector peers
Valuation20
Growth86
Profitability65
Financial health80
Dividends–

Five-year price chart navy: price · brown: 200-day average · blue band: fair value range

157277397516636Fair value $2872021-102023-012024-042025-072026-10

Executive summary

Intuitive Surgical makes the da Vinci robotic-assisted surgical systems, which surgeons use to perform minimally invasive procedures, along with the Ion system for lung biopsy. Hospitals acquire or lease the systems, and then order instruments, accessories and service plans for them. Revenue therefore combines system sales and leases with recurring income from instruments and services that rise with the number of procedures performed.

Sales reached $11.0 billion in the last twelve months, having grown 17.4% a year over the past three years. Operating profit equals 31.3% of revenue. Return on invested capital is 22%. No dividend is paid. These numbers describe past results and current financial position, and they are shown for reference only.

StocksXray gives Intuitive Surgical Inc an X-Ray Score of 61 out of 100 (high confidence), ahead of 72% of the S&P 500 stocks in its sector. Its strongest lens is growth (86) and its weakest is valuation (20).

Our fair value blend is $287.30 (range $256.77 to $316.61). At $426.70 the stock trades 49% above that blend, so the label is "Overvalued" with medium model uncertainty. Fair value is a range, not a price target.

stocksxray.com · page 1
XStocksXray
Intuitive Surgical Inc (ISRG)

Valuation history multiples at each fiscal year-end price; the last column uses today's price and the last twelve months

FY2021FY2022FY2023FY2024FY2025Now
Price$359.30$265.35$337.36$521.96$566.36$426.70
Market cap$131.4B$96.1B$120.6B$188.9B$205.4B$152.5B
P/E77.1×72.7×67.1×81.3×72.0×49.0×
EV / revenue22.3×14.8×16.2×22.2×19.8×13.4×
EV / EBITDA69.9×58.3×65.3×78.8×67.8×42.7×
Price / free cash flow75.1×100.2×160.8×144.9×82.5×47.3×
Free-cash-flow yield1.3%1.0%0.6%0.7%1.2%2.1%
Price / book11.0×8.7×9.1×11.5×11.5×8.4×
Dividend yield––––––

Fundamentals checklist ● 9 Good · ● 3 Average · ● 3 Bad · each check graded against the sector

Cash quality

Earnings backed by cash−2.7%Average
Free-cash-flow yield2.1%Bad

Risk models

Altman Z score12.0×Good
Piotroski F-Score7 of 9Average

Growth

EPS growth (3y)29.2%Good
Free-cash-flow growth (3y)37.5%Good
Revenue growth (3y)17.4%Good
Growth consistency100%Good

Balance sheet

Current ratio5.0×Good
Interest coverno interest costGood

Valuation

Fair value vs price0.7×Bad
EBIT / EV yield2.3%Bad

Profitability

Return on invested capital22.1%Good
Operating margin31.3%Good
Gross profitability35.2%Average
stocksxray.com · page 2
XStocksXray
Intuitive Surgical Inc (ISRG)

Financials US$ millions, from SEC filings; last column is the last twelve months

Income statementFY21FY22FY23FY24FY25LTM
Revenue5,7106,2227,1248,35210,06511,034
Gross profit3,9594,1964,7305,6346,6427,358
Operating income1,8211,5771,7672,3492,9463,451
Net income1,7051,3221,7982,3232,8563,139
Diluted EPS ($)4.663.655.036.427.878.71
Free cash flow1,7509587501,3042,4913,223
Gross margin69.3%67.4%66.4%67.5%66.0%66.7%
Operating margin31.9%25.3%24.8%28.1%29.3%31.3%
Net margin29.9%21.3%25.2%27.8%28.4%28.4%
Balance sheetFY21FY22FY23FY24FY25LTM
Total assets13,55512,97415,44218,74320,45920,877
Cash1,2911,5812,7502,0273,3682,760
Total debt––––––
Equity11,90111,04213,30816,43417,82418,168
Dividend per share ($)––––––

Revenue and net income US$ billions: navy revenue, teal net income

FY21FY22FY23FY24FY25

Margins blue gross, teal operating, brown net

0%23%46%69%FY21FY22FY23FY24FY25

Latest quarters

Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue ($M)2,2532,4402,5052,8662,7712,892
Growth vs a year earlier+19.2%+21.4%+22.9%+18.8%+23.0%+18.5%
Net income ($M)698658704795822818
Diluted EPS ($)1.921.811.95–2.282.29
stocksxray.com · page 3
XStocksXray
Intuitive Surgical Inc (ISRG)

Peers in Health Care Equipment

CompanyX-Ray
ISRG · Intuitive Surgical Inc61
RMD · Resmed Inc73
DXCM · Dexcom Inc71
PODD · Insulet Corp69
IDXX · Idexx Laboratories Inc67

Market Compass outlook for Health Care: Neutral (51/100). It blends regime history, macro sensitivity, momentum and valuation.

Returns

1 week+0.6%
1 month+11.3%
3 months+20.8%
6 months−9.1%
1 year−2.0%
3 years+51.4%
5 years+29.9%

Technical summary

DailyBullish10 bullish · 1 neutral · 5 bearish
WeeklyNeutral6 bullish · 1 neutral · 5 bearish
MonthlyStrongly bearish1 bullish · 1 neutral · 6 bearish
50-day / 200-day average$391.67 / $439.63
52-week low / high$328.57 / $603.88
Classic pivot, support and resistanceS2 419.65 · S1 423.18 · P – · R1 432.56 · R2 438.41
stocksxray.com · page 4
XStocksXray
Intuitive Surgical Inc (ISRG)

Strengths

  • Return on invested capital of 22.1% is ahead of 79% of its sector peers.
  • Operating margin of 31.3% is ahead of 91% of its sector peers.
  • Revenue growth of 17.4% a year over three years is ahead of 96% of its sector peers.
  • Interest cover of no interest cost is ahead of 82% of its sector peers.
  • Piotroski F-Score of 7 out of 9: most of the nine accounting health tests pass.

Risks and weak spots

  • Free-cash-flow yield is weak against Health Care peers (2.1%).
  • Fair value vs price is weak against Health Care peers (0.7×).
  • EBIT / EV yield is weak against Health Care peers (2.3%).
  • The price is above our fair value range, so good news may already be in the price.

Latest SEC filings

DateFormItems
27 Jul 20268-K5.03,9.01
21 Jul 202610-Q
16 Jul 20268-K2.02,9.01
28 May 20268-K5.02,9.01
4 May 20268-K5.02,5.07,7.01
22 Apr 202610-Q
21 Apr 20268-K2.02,9.01
13 Mar 2026DEF 14A

How to read this report

Every number comes from SEC filings, end-of-day prices and the StocksXray models described on the methodology page. The X-Ray Score ranks each metric against the company's own sector. Fair value blends three models and carries a typical error of about 40%, so treat it as a range. Analyst ratings, price targets and earnings-call summaries are not part of this report. Educational research, not financial advice; read the disclaimer.

stocksxray.com · page 5 · generated 19 Oct 2026